Q32 Bio | BiotechTV

top of page

State of Possible: Q32 Bio has a key phase 2 readout for its IL-7Rα in alopecia scheduled for this summer - CEO Jodie Morrison explains the science and previews it

She describes how Q32's therapy, bempikibart, is almost like a natural bispecific because it blocks both IL-7 and TSLP. It could be the first biologic developed for this condition.

Company News

2 days ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

State of Possible: Q32 Bio has a key phase 2 readout for its IL-7Rα in alopecia scheduled for this summer - CEO Jodie Morrison explains the science and previews it

Follow BiotechTV

Sponsors

Sponsor Spotlight